Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2021.02.053
- Author:
Xiao-Feng CHEN
1
;
Meng WANG
1
;
Feng ZHANG
1
;
Jia-Jia LI
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233003, Anhui Province, China.
2. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233003, Anhui Province, China,E-mail: 4119469 @ qq.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
Circulating Tumor DNA;
Humans;
Lymphoma, Large B-Cell, Diffuse/genetics*;
Polymerase Chain Reaction;
Prognosis
- From:
Journal of Experimental Hematology
2021;29(2):638-642
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) as an aggressive lymphoma, there has not a good molecular marker to assess the therapeutic efficacy and prognosis of the disease. As compared with the traditional deteation method, it was found that the circulating tumor DNA (ctDNA) can be used as a non-invasive specific biomarker which can dynamically provide the information about the lymphoma. ctDNA in DLBCL can be obtained by dideoxy chain termination method combined with PCR, so as to detect genetic markers, targeted sequences of gene which is related to lymphoma; the digital PCR (dPCR) for lymphoma somatic mutations and the detection of abnormal methylation; ctDNA is closely related to the diagncsis, therapeutic efficiency and prognosis of DLBCL, thus ctDNA can be used for the early detection, mid-term and prognostic monitoring in DLBCL, which makes ctDNA have a broad clinical applied prospect.
